Latest Breaking News On - Nasdaq fdmt - Page 15 : comparemela.com

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic.

United statesRobert kimCagri besirliDavid kirnKellogg eye centerAmerican society of retina specialistsUniversity of michiganMolecular therapeuticsAmerican societyRetina specialistsTherapeutic vector evolutionChief executive officerSenior vice presidentClinical therapeutic area headClinical data summaryNasdaq fdmt